Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

305 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir.
González-Cordón A, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Stellbrink HJ, Guaraldi G, Masiá M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Behrens G, Pozniak A, Gatell JM, Martínez E; NEAT 022 Study Group. González-Cordón A, et al. Among authors: moyle g. J Antimicrob Chemother. 2023 Sep 5;78(9):2361-2365. doi: 10.1093/jac/dkad247. J Antimicrob Chemother. 2023. PMID: 37539492
Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV.
González-Cordón A, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Stellbrink HJ, Guaraldi G, Masiá M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Behrens G, Pozniak A, Gatell JM, Martínez E; NEAT022 Study Group. González-Cordón A, et al. Among authors: moyle g. J Antimicrob Chemother. 2021 Aug 12;76(9):2380-2393. doi: 10.1093/jac/dkab158. J Antimicrob Chemother. 2021. PMID: 34120186 Clinical Trial.
Incidence of Hypertension and Blood Pressure Changes in Persons With Human Immunodeficiency Virus at High Risk for Cardiovascular Disease Switching From Boosted Protease Inhibitors to Dolutegravir: A Post-hoc Analysis of the 96-week Randomised NEAT-022 Trial.
Sempere A, Assoumou L, González-Cordón A, Waters L, Rusconi S, Domingo P, Gompels M, de Wit S, Raffi F, Stephan C, Masiá M, Rockstroh J, Katlama C, Behrens GMN, Moyle G, Johnson M, Fox J, Stellbrink HJ, Guaraldi G, Florence E, Esser S, Gatell J, Pozniak A, Martínez E; NEAT 022 Study Group. Sempere A, et al. Among authors: moyle g. Clin Infect Dis. 2023 Oct 5;77(7):991-1009. doi: 10.1093/cid/ciad297. Clin Infect Dis. 2023. PMID: 37207617
Antiretrovirals and Weight Change: Weighing the Evidence.
Wohl DA, Koethe JR, Sax PE, McComsey GA, Kuritzkes DR, Moyle G, Kaplan L, van Wyk J, Campo RE, Cohen C. Wohl DA, et al. Among authors: moyle g. Clin Infect Dis. 2024 Apr 12:ciae191. doi: 10.1093/cid/ciae191. Online ahead of print. Clin Infect Dis. 2024. PMID: 38606799
Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial.
Moyle G, Assoumou L, de Castro N, Post FA, Curran A, Rusconi S, De Wit S, Stephan C, Raffi F, Johnson M, Masia M, Vera J, Jones B, Grove R, Fletcher C, Duffy A, Morris K, Pozniak A; NEAT ID Foundation and the WISARD study group. Moyle G, et al. Lancet HIV. 2024 Mar;11(3):e156-e166. doi: 10.1016/S2352-3018(23)00292-8. Lancet HIV. 2024. PMID: 38417976 Clinical Trial.
Building a transdisciplinary expert consensus on the cognitive drivers of performance under pressure: An international multi-panel Delphi study.
Albertella L, Kirkham R, Adler AB, Crampton J, Drummond SPA, Fogarty GJ, Gross JJ, Zaichkowsky L, Andersen JP, Bartone PT, Boga D, Bond JW, Brunyé TT, Campbell MJ, Ciobanu LG, Clark SR, Crane MF, Dietrich A, Doty TJ, Driskell JE, Fahsing I, Fiore SM, Flin R, Funke J, Gatt JM, Hancock PA, Harper C, Heathcote A, Heaton KJ, Helsen WF, Hussey EK, Jackson RC, Khemlani S, Killgore WDS, Kleitman S, Lane AM, Loft S, MacMahon C, Marcora SM, McKenna FP, Meijen C, Moulton V, Moyle GM, Nalivaiko E, O'Connor D, O'Conor D, Patton D, Piccolo MD, Ruiz C, Schücker L, Smith RA, Smith SJR, Sobrino C, Stetz M, Stewart D, Taylor P, Tucker AJ, van Stralen H, Vickers JN, Visser TAW, Walker R, Wiggins MW, Williams AM, Wong L, Aidman E, Yücel M. Albertella L, et al. Among authors: moyle gm. Front Psychol. 2023 Jan 18;13:1017675. doi: 10.3389/fpsyg.2022.1017675. eCollection 2022. Front Psychol. 2023. PMID: 36755983 Free PMC article.
305 results